Intravenous belimumab plus SOC vs placebo plus SOC was not linked to an increased risk for infection among patients with SLE.

Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the promotion of Sanam Pangali to ...

Viewing lupus decision aids without interruption leads to better patient-reported outcomes, regardless of whether they are ...

Patients with systemic lupus erythematosus with a history of cutaneous lupus erythematosus are more likely to have high ...

The thymus functions as the primary lymphoid organ responsible for the generation of T cells and plays a crucial role in preventing autoimmune reactions by eliminating autoreactive cells before ...

You might associate autoimmune conditions with symptoms like skin disease, chronic pain, and fatigue. A less-discussed ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

Incorporating systemic lupus erythematosus disease activity score (SLEDAS) criteria may enhance treat-to-target strategies ...

The FDA has approved Benlysta for SC administration using an autoinjector in patients 5 years of age and older with active LN.

Meanwhile, RemeGen can acquire around 23% of Vor Bio's enlarged issued share capital through the $80 million in warrants, in ...

The incidence and prevalence of CTD-ILD in the US is most common among women and older individuals, affecting approximately 116,000 to 118,000 adults.

Magnetic resonance imaging (MRI) findings such as inflammatory-type lesions and myelopathies are significantly associated with attribution of neuropsychiatric (NP) events to systemic lupus ...